301301 Stock Overview
Engages in the research and development, and industrialization of biological fermentation technology in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 301301 from our risk checks.
Yili Chuanning Biotechnology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.80 |
| 52 Week High | CN¥18.33 |
| 52 Week Low | CN¥6.94 |
| Beta | 0 |
| 11 Month Change | -4.83% |
| 3 Month Change | 18.08% |
| 1 Year Change | 36.61% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 34.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301301 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -6.4% | -2.6% | -2.1% |
| 1Y | 36.6% | -20.9% | 2.8% |
Return vs Industry: 301301 exceeded the CN Biotechs industry which returned -17.3% over the past year.
Return vs Market: 301301 exceeded the CN Market which returned 5.4% over the past year.
Price Volatility
| 301301 volatility | |
|---|---|
| 301301 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 301301 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301301's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 2,881 | Xuheng Deng | www.klcnsw.com |
Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid.
Yili Chuanning Biotechnology Co.,Ltd. Fundamentals Summary
| 301301 fundamental statistics | |
|---|---|
| Market cap | CN¥28.51b |
| Earnings (TTM) | CN¥1.38b |
| Revenue (TTM) | CN¥5.70b |
20.7x
P/E Ratio5.0x
P/S RatioIs 301301 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301301 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.70b |
| Cost of Revenue | CN¥3.69b |
| Gross Profit | CN¥2.00b |
| Other Expenses | CN¥628.21m |
| Earnings | CN¥1.38b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 35.18% |
| Net Profit Margin | 24.15% |
| Debt/Equity Ratio | 18.6% |
How did 301301 perform over the long term?
See historical performance and comparison